Efficacy and Tolerability of a Combination of Lyprinol and High Concentrations of EPA and DHA in Inflammatory Rheumatoid Disorders

Adv Ther. May-Jun 2004;21(3):197-201. doi: 10.1007/BF02850125.

Abstract

This 12-week drug-monitoring study was conducted to evaluate the efficacy of Sanhelios Mussel Lyprinol Lipid Complex on 50 adult men and women with inflammatory rheumatoid arthritis. A total of 34 patients required drug therapy before and during the study. By the end of the study, 21 (62%) patients were able to reduce their dosage and 13 were able to terminate drug therapy. At the end of the treatment period, 38% were regarded symptom free, and the number of patients with severe pain decreased significantly from 60% at baseline to 25% at the completion of the trial. A significant effect was observed for each investigated parameter. The special combination of Lyprinol and omega-3 fatty acids was generally very well tolerated, with only one, nonserious adverse event (mild nausea) reported. This dietary supplement may therefore be considered an effective and well-tolerated component of treatment regimens for inflammatory rheumatoid arthritis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Arthritis, Rheumatoid / diagnosis*
  • Arthritis, Rheumatoid / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Eicosapentaenoic Acid / administration & dosage*
  • Female
  • Follow-Up Studies
  • Humans
  • Lipids / administration & dosage*
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Pain Measurement
  • Prospective Studies
  • Pyrones / administration & dosage*
  • Range of Motion, Articular / drug effects
  • Range of Motion, Articular / physiology
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Lipids
  • Pyrones
  • lyprinol
  • dehydroacetic acid
  • Eicosapentaenoic Acid